Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Arvinas in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($1.84) for the year. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share.
Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. The firm's revenue for the quarter was up 646.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.97) EPS.
ARVN has been the subject of several other research reports. Wedbush lowered shares of Arvinas from an "outperform" rating to a "neutral" rating and decreased their price target for the stock from $57.00 to $12.00 in a research note on Wednesday, March 12th. TD Cowen lowered Arvinas from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Wells Fargo & Company dropped their price target on Arvinas from $26.00 to $19.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Leerink Partnrs lowered Arvinas from a "strong-buy" rating to a "hold" rating in a report on Sunday, June 1st. Finally, Piper Sandler restated an "overweight" rating and issued a $14.00 price objective (down from $24.00) on shares of Arvinas in a research note on Friday, May 2nd. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Arvinas presently has a consensus rating of "Moderate Buy" and an average target price of $20.29.
Read Our Latest Report on ARVN
Arvinas Stock Down 1.0%
NASDAQ ARVN traded down $0.08 during trading hours on Wednesday, reaching $7.59. 492,885 shares of the company were exchanged, compared to its average volume of 1,416,747. The stock has a market capitalization of $554.00 million, a P/E ratio of -2.74 and a beta of 2.19. Arvinas has a 1 year low of $5.90 and a 1 year high of $34.11. The business's 50 day simple moving average is $7.33 and its 200-day simple moving average is $13.79.
Institutional Trading of Arvinas
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. raised its position in Arvinas by 1.6% in the 4th quarter. Invesco Ltd. now owns 37,254 shares of the company's stock worth $714,000 after purchasing an additional 581 shares during the period. Rhumbline Advisers grew its stake in shares of Arvinas by 0.9% during the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company's stock valued at $1,685,000 after buying an additional 754 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of Arvinas by 2.7% in the fourth quarter. Bank of Montreal Can now owns 39,407 shares of the company's stock worth $755,000 after buying an additional 1,044 shares during the period. KBC Group NV increased its holdings in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after buying an additional 1,255 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Arvinas by 3.8% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,514 shares of the company's stock valued at $700,000 after acquiring an additional 1,353 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company's stock.
Insider Activity
In related news, insider Noah Berkowitz sold 8,658 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the transaction, the insider now owns 110,023 shares of the company's stock, valued at $945,097.57. This represents a 7.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.73% of the company's stock.
Arvinas Company Profile
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
See Also
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
